These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 30346642)

  • 1. The Fourth Hurdle: Commentary on "Weighing Of Evidence By Health Technology Assessment Bodies: Retrospective Study Of Reimbursement Recommendations For Conditionally Approved Drugs" by Vreman et al.
    Honig PK
    Clin Pharmacol Ther; 2019 Mar; 105(3):561-562. PubMed ID: 30346642
    [No Abstract]   [Full Text] [Related]  

  • 2. Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs.
    Vreman RA; Bouvy JC; Bloem LT; Hövels AM; Mantel-Teeuwisse AK; Leufkens HGM; Goettsch WG
    Clin Pharmacol Ther; 2019 Mar; 105(3):684-691. PubMed ID: 30300938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland.
    Schmitz S; McCullagh L; Adams R; Barry M; Walsh C
    Pharmacoeconomics; 2016 Sep; 34(9):925-37. PubMed ID: 27034245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of patient outcomes and cost aspects on reimbursement recommendations in Poland in 2012-2014.
    Malinowski KP; Kawalec P; Trąbka W
    Health Policy; 2016 Nov; 120(11):1249-1255. PubMed ID: 27884491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relating Health Technology Assessment recommendations and reimbursement decisions in Poland in years 2012-2014, a retrospective analysis.
    Kawalec P; Malinowski KP
    Health Policy; 2016 Nov; 120(11):1240-1248. PubMed ID: 28029415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH common drug review.
    Janoudi G; Amegatse W; McIntosh B; Sehgal C; Richter T
    Orphanet J Rare Dis; 2016 Dec; 11(1):164. PubMed ID: 27908281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Framework for describing and classifying decision-making systems using technology assessment to determine the reimbursement of health technologies (fourth hurdle systems).
    Hutton J; McGrath C; Frybourg JM; Tremblay M; Bramley-Harker E; Henshall C
    Int J Technol Assess Health Care; 2006; 22(1):10-8. PubMed ID: 16673675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'Fourth hurdle reviews', NICE, and database applications.
    Paul JE; Trueman P
    Pharmacoepidemiol Drug Saf; 2001; 10(5):429-38. PubMed ID: 11802589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prevalence of child-specific utilities in NICE appraisals for paediatric indications: rise of the economic orphans?
    Montgomery SM; Kusel J
    Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):347-50. PubMed ID: 27082293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health technology assessments in personalized medicine: illustrations for cost-effectiveness analysis.
    Postma MJ; Boersma C; Vandijck D; Vegter S; Le HH; Annemans L
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):367-9. PubMed ID: 21831013
    [No Abstract]   [Full Text] [Related]  

  • 11. The importance of subjective values to medical technology assessment and health policy.
    Diamond GA
    J Invasive Cardiol; 1993; 5(1):17-22. PubMed ID: 10148297
    [No Abstract]   [Full Text] [Related]  

  • 12. Trends and determinants in reimbursement decision-making in Poland in the years 2013-2015.
    Kawalec P; Malinowski KP; Trąbka W
    Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):197-205. PubMed ID: 28952400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health technology assessment and economic evaluation across jurisdictions.
    Simoens S
    Value Health; 2010; 13(6):857-9. PubMed ID: 20701730
    [No Abstract]   [Full Text] [Related]  

  • 14. Health technology assessment and policy from the economic perspective.
    Rutten F
    Int J Technol Assess Health Care; 2004; 20(1):67-70. PubMed ID: 15176179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A theoretical and empirical investigation into the willingness-to-pay function for new innovative drugs by Germany's health technology assessment agency (IQWiG).
    Gandjour A
    Health Serv Manage Res; 2013 Nov; 26(4):103-9. PubMed ID: 25595007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Issues for countries considering introducing the "fourth hurdle": the case of Hungary.
    Gulácsi L; Boncz I; Drummond M
    Int J Technol Assess Health Care; 2004; 20(3):337-41. PubMed ID: 15446763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reimbursement programs and health technology assessment for diabetes devices and supplies: a Canadian perspective.
    Cheung RY; Mui V
    J Diabetes Sci Technol; 2015 May; 9(3):706-10. PubMed ID: 25697719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The transparency of published health technology assessment-based recommendations on pharmaceutical reimbursement in Poland.
    Bochenek T; Kocot E; Rodzinka M; Godman B; Maciejewska K; Kamal S; Pilc A
    Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):385-400. PubMed ID: 27882823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An economic theory of the fourth hurdle.
    Rogowski WH
    Health Econ; 2013 May; 22(5):600-10. PubMed ID: 22544431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attitudes toward supplementary criteria in the reimbursement process in Poland.
    Kolasa K; Annemans L; Lees M
    Int J Technol Assess Health Care; 2013 Oct; 29(4):443-9. PubMed ID: 24290338
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.